Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kite Pharma Inc.

Division of Gilead Sciences Inc.
www.kitepharma.com

Latest From Kite Pharma Inc.

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

ImmunoOncology Research & Development

Finance Watch: Cell And Gene Therapies Buck 2019’s Venture Capital Trend

Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.

Financing Regenerative Medicine

ASH First Look: CAR-T Therapies Against BCMA, CD19 And More

CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets. 

Clinical Trials Research and Development Strategies

EMA Accepts First Diabetes Drug Onto PRIME

Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.

Drug Review Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • Christi L Shaw, CEO
  • Contact Info
  • Kite Pharma Inc.
    Phone: (650) 574-3000
    333 Lakeside Dr.
    Foster City, CA 90404
    USA
UsernamePublicRestriction

Register